Loading...
  • severe
  • Severe bone marrow suppression is a relative contraindication to idarubicin depending upon the etiology of the suppression. (pdr.net)
  • clinical
  • Angina and arrhythmias are relative contraindications to idarubicin therapy, depending on the degree of clinical impairment. (pdr.net)
  • bone
  • Concentrations of idarubicin and idarubicinol in nucleated blood and bone marrow cells are more than a hundred times the plasma concentrations. (nih.gov)
  • combination
  • The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine. (nih.gov)
  • side effects
  • In the few studies that have been conducted on the oral formulation of idarubicin, the most prominent side effects seen are low blood cell counts, nausea, vomiting, diarrhea , and hair loss. (encyclopedia.com)
  • receive
  • 50%), recent or acute myocardial infarction, or cardiac arrhythmias are not good candidates to receive idarubicin. (pdr.net)